الصفحة الرئيسية>>Signaling Pathways>> Cardiovascular>> Vasoconstriction>>Desglymidodrine

Desglymidodrine (Synonyms: ST 1059)

رقم الكتالوجGC52051

Desglymidodrine (ST 1059) ، المستقلب النشط للميدودرين ، هو ناهض انتقائي لمستقبلات ألفا 1

Products are for research use only. Not for human use. We do not sell to patients.

Desglymidodrine التركيب الكيميائي

Cas No.: 3600-87-1

الحجم السعر المخزون الكميّة
1 mg
46٫00
متوفر
5 mg
138٫00
متوفر
10 mg
230٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Desglymidodrine is the active metabolite of the prodrug midodrine .1 It is formed from midodrine by enzymatic hydrolysis.2 Desglymidodrine is an agonist of α1-adrenergic receptors (α1-ARs).1 It binds to α1-ARs (Kis = 9.77, 9.55, and 8.51 µM for α1A, α1B, and α1D-ARs, respectively) and increases intraurethral pressure (IUP) and mean arterial pressure (MAP) by 5 and 20 mm Hg, respectively, in anesthetized dogs at doses of 205 and 250 nmol/kg, respectively.

1.Altenbach, R.J., Khilevich, A., Kolasa, T., et al.Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing α1A-adrenoceptor agonistJ. Med. Chem.47(12)3220-3235(2004) 2.McClellan, K.J., Wiseman, L.R., and Wilde, M.I.Midodrine. A review of its therapeutic use in the management of orthostatic hypotensionDrugs Aging12(1)76-86(1998)

مراجعات

Review for Desglymidodrine

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Desglymidodrine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.